Amneal Reports Fourth Quarter and Full Year 2021 Financial Results

‒ Q4 2021 Net Revenue of $537 million; GAAP Net Loss of $6 million; Diluted Loss per Share of $0.04 ‒‒ Q4 2021 Adjusted Net Income of $54 million (1), Adjusted EBITDA (1) of $126 million; Adjusted Diluted EPS (1) of $0.18 ‒‒ Full Year Net Revenue of $2.1 billion; GAAP Net Income of $11 million; Diluted EPS of $0.07...

Related Keywords

United States ,America ,Chintu Patel ,Exchange Commission ,Amneal Group ,Drug Administration ,Amneal Pharmaceuticals Inc ,Diluted Loss ,Net Income ,Adjusted Diluted ,Full Year Net Revenue ,Full Year ,Amneal Pharmaceuticals ,Co Chief Executive ,Eastern Time ,Investor Relations ,Securities Litigation Reform Act ,Common Stock ,Annual Report ,Ended December ,